Clinical Pharmacokinetics of Mirtazapine

@article{Timmer2000ClinicalPO,
  title={Clinical Pharmacokinetics of Mirtazapine},
  author={Cees J. Timmer and J. M. A. Sitsen and Leon P. C. Delbressine},
  journal={Clinical Pharmacokinetics},
  year={2000},
  volume={38},
  pages={461-474}
}
Mirtazapine is the first noradrenergic and specific serotonergic antidepressant (‘NaSSA’). It is rapidly and well absorbed from the gastrointestinal tract after single and multiple oral administration, and peak plasma concentrations are reached within 2 hours. Mirtazapine binds to plasma proteins (85%) in a nonspecific and reversible way.The absolute bioavailability is approximately 50%, mainly because of gut wall and hepatic first-pass metabolism. Mirtazapine shows linear pharmacokinetics over… Expand
Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats.
TLDR
Limited serum sampling during the pharmacodynamic study revealed drug exposure comparable with the pharmacokinetic study, but no correlation between exposure and food consumed, and mirtazapine does not appear to display linear pharmacokinetics in cats. Expand
Pharmacokinetics of Mirtazapine and Its Main Metabolites after Single Oral Administration in Fasting/Fed Horses
TLDR
The pharmacokinetic parameters demonstrated in this study suggest that MRZ is suitable for oral administration in the horse, however, further investigations are required to evaluate both its safety and effectiveness in this animal species. Expand
MIRTAZAPINE PHARMACOKINETICS IN HEALTHY THAI VOLUNTEERS
Mirtazapine (MZP) is a thirdgeneration antidepress ant with a dual mode of action. To investigate the pharmacokinetic profile of MZP in 22 healthy Thai volunteers (12 males, 10 females), eachExpand
Population pharmacokinetic analysis of mirtazapine
TLDR
The variability of mirtazapine plasma concentrations in clinical routine is caused to a relevant degree by CYP2D6, and should be taken into account when therapeutic drug monitoring is carried out to check treatment adherence or when a special clinical situation demands careful dosing of this drug. Expand
A review of the pharmacological and clinical profile of mirtazapine.
TLDR
The novel antidepressant mirtazapine has a dual mode of action that enhances the release of norepinephrine and 5-HT1A-mediated serotonergic transmission and seems to be safe and effective during long-term use. Expand
Tissue distribution of mirtazapine and desmethylmirtazapine in a case of mirtazapine poisoning.
TLDR
The concentration determined in a brain sample suggests a contribution of the metabolite to the drug's pharmacodynamic activity, and significant adverse or synergistic effects among the drugs detected as well as adverse reactions such as a serotonin reaction appeared less probable. Expand
Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients.
TLDR
Initial mirtazapine concentration and C/D ratio did not show an association with responsiveness in depressive patients, and a further study could be helpful for clinical decision making based on the characteristics of patients. Expand
Multicenter Study on the Clinical Effectiveness, Pharmacokinetics, and Pharmacogenetics of Mirtazapine in Depression
TLDR
Evaluating the relationship between the efficacy of mirtazapine and the steady-state plasma concentrations of its enantiomers and metabolites in moderately to severely depressed patients, taking their pharmacogenetic status into account found no evidence for a significant plasma concentration–clinical effectiveness relationship regarding any pharmacokinetic parameter. Expand
PHARMACOKINETICS A ND D ISPOSITION
TLDR
The variability of mirtazapine plasma concentrations in clinical routine is caused to a relevant degree by CYP2D6, and should be taken into account when therapeutic drug monitoring is carried out to check treatment adherence or when a special clinical situation, such as co-morbidity and add-on medication, demands careful dosing of this drug. Expand
Effects of Age and Sex on the Pharmacokinetics, Safety, and Tolerabilityof Oral Desvenlafaxine in Healthy Adults
TLDR
The pharmacokinetics, safety, and tolerability of a single oral dose of desvenlafaxine were assessed in healthy adults stratified by age and sex in an open-label, inpatient trial and it was generally well tolerated and was slowly absorbed in all age groups. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing
The absolute bioavailability of mirtazapine, the active constituent of Remeron® tablets, a new antidepressant developed under the laboratory code Org 3770, was assessed in eight healthy young maleExpand
Pharmacokinetic dose‐proportionality study at steady state of mirtazapine from Remeron® tablets
Steady‐state dose proportionality of mirtazapine, the active constituent of Remeron® tablets, a new antidepressant developed under the laboratory code Org 3770, was investigated. Each of 27 youngExpand
Pharmacokinetics and Biotransformation of Mirtazapine in Human Volunteers
TLDR
The results showed that the area under the plasma drug concentration-time curve (AUC) of mirtzapine in human plasma appeared to be three times higher than the AUC of demethylmirtazapine. Expand
Pharmacokinetics of Mirtazapine from Orally Administered Tablets: Influence of Gender, Age and Treatment Regimen
TLDR
In all groups, chronic dosing resulted in approximately 10 per cent higher plasma levels at steady state than those predicted from the single‐dose kinetic profile of mirtazapine, although statistically significant effects of gender and of age were observed. Expand
Mirtazapine oral single dose kinetics in patients with different degrees of renal failure
TLDR
The single morning 15 mg/day dose of mirtazapine was well tolerated by patients with renal failure, irrespective of degree of severity, and further research is needed to evaluate repeated dose pharmacokinetics and tolerability. Expand
Pharmacokinetics of mirtazapine and lithium in healthy male subjects
TLDR
The results indicate that mirtazapine does not alter the pharmacokinetics of lithium and vice versa, and the combination of mirtzapine and lithium appeared to be safe and well-tolerated. Expand
Concomitant use of mirtazapine and phenytoin: a drug–drug interaction study in healthy male subjects
TLDR
Co-administration of mirtazapine did not alter the steady-state pharmacokinetics of phenytoin and induction of CYP 3A3/4 was confirmed by the significantly increased 6β-hydroxycortisol/cortsisol ratio. Expand
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study
TLDR
Data from one patient suggest that adding risperidone to mirtazapine does not result in clinically relevant changes in plasma concentrations of either compound, and probably does not necessitate a change of the dosage of either drug. Expand
Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables.
TLDR
Thiothixene clearance was found to be significantly increased by enzyme inducing drugs and decreased by clearance inhibiting agents and tobacco smoking within the no interactions and inhibitor groups, but not in the inducer group. Expand
In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans
TLDR
In vivo study indicates that the major enantiomer of mirtazapine in plasma is not metabolised by CYP2D6, but it cannot be excluded that the minor one is, while a study using a chiral analysis of the 2 enantiomers is currently ongoing. Expand
...
1
2
3
4
...